Travere Therapeutics (TVTX) Net Equity Issued and Repurchased (2013 - 2022)

Travere Therapeutics' Net Equity Issued and Repurchased history runs 6 years deep, the most recent figure standing at -$20.1 million for Q4 2022.

• Quarterly Net Equity Issued and Repurchased fell 110.9% year-over-year to -$20.1 million in Q4 2022, while the trailing twelve-month figure through Sep 2022 was $204.5 million (up 354.63% YoY) and the FY2024 annual result came in at $134.7 million, down 29.53% from the prior year.
• Net Equity Issued and Repurchased was -$20.1 million for Q4 2022 at Travere Therapeutics, down from $20.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $184.4 million in Q4 2021 and bottomed at -$85.2 million in Q4 2020.
• A 3-year average of $26.6 million and a median of $2.4 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased soared 316.45% — and 2022, when it plunged 110.9%.
• Travere Therapeutics' Net Equity Issued and Repurchased stood at -$85.2 million in 2020, then surged by 316.45% to $184.4 million in 2021, then sank by 110.9% to -$20.1 million in 2022.
• Business Quant data shows TVTX's Net Equity Issued and Repurchased at -$20.1 million in Q4 2022, $20.1 million in Q1 2022, and $184.4 million in Q4 2021.